Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Core Insights - Replimune Group, Inc. is set to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025, at 2:15 PM PT [1] Company Overview - Replimune Group, Inc. is a clinical stage biotechnology company founded in 2015, headquartered in Woburn, MA, focused on developing novel oncolytic immunotherapies [3] - The company's proprietary RPx platform utilizes a potent HSV-1 backbone aimed at maximizing immunogenic cell death and inducing a systemic anti-tumor immune response [3] - The RPx platform is designed for dual local and systemic activity, enabling direct virus-mediated tumor killing, releasing tumor-derived antigens, and modifying the tumor microenvironment to foster a strong systemic immune response [3] - Replimune's product candidates are expected to work synergistically with established and experimental cancer treatments, allowing for versatile development either alone or in combination with other therapies [3]